Novo Holdings
在场
Novo Holdings 的所有者是 Novo Nordisk.
是其中之一......
- Forbes Global 2000 (#205);
- Fortune 500 Europe (#116);
- Global Fortune 500 (#469);
- Stoxx 600;
- TOB Iconic 10,000.
Novo Nordisk 是一家在股票代码 NOVO (DK) 下上市的公司。
Novo Nordisk 在 11 个国家有直接业务。Novo Nordisk 拥有 16家子公司，其中包括 Cardior Pharmaceuticals、Dicerna Pharmaceuticals 和 Inversago Pharma。
他们在：
涉及Novo Nordisk的并购和融资。
- Novo Holdings has announced the acquisition of Catalent Pharma Solutions (公布2024二月8号).
- Novo Holdings has announced the acquisition of Paratek Pharmaceuticals (公布2023九月27号).
- Novo Holdings has announced the acquisition of Paratek Pharmaceuticals (公布2023六月7号).
高管
控股公司
Novo Nordisk 拥有 1,329 家竞争者，其中包括 Berkshire Hathaway (美国(美洲))、Amundi (法国) 和 Tata Sons (印度)。
Popular M&A news in 控股公司
- Aurora Investment Trust的新名称是Aurora UK Alpha plc。 (公布2024十二月4号).
- BlackRock has announced the acquisition of HPS Investment Partners (公布2024十一月28号).
- Alliance Witan的新名称是Alliance Witan。 (公布2024十月29号).
控股公司 行业的其他推荐联系人
消息
Novo Holdings 的最新新闻稿
- Novo Holdings participates in €80 million Series A financing round for Antag Therapeutics, supporting the advancement of novel obesity treatments
- Novo Holdings to acquire Benchmark Genetics, a leader in aquaculture genetics
- Novo Holdings joins $135 million Series B financing for Adcendo
- Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates (ADCs) for solid tumours
- Novo Holdings Leads Kivu Bioscience’s $92 Million Series A Financing to Support Advancement of Next-Generation Antibody-Drug Conjugates
- The Science Based Target initiative (SBTi) approves Novo Holdings’ emissions reduction targets
- Novo Holdings Leads AvenCell’s $112 Million Series B Financing to Advance Next-Generation Cell Therapy Treatments
- Novo Holdings Launches Portfolio Company Booster Therapeutics to Advance New Class of Small Molecule Proteasome Activator Therapeutics
- Novo Holdings to acquire majority stake in Stingray Marine Solutions, a leading provider of aquaculture technology
- Novo Holdings Expands MedTech Portfolio with Investment in Route 92 Medical
- View more press releases Close
关于 Novo Holdings 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Kasim Kutay 
